{"schema_version":"1","generated_at":"2026-11-21T09:49:35.397Z","data_as_of":null,"url":"https://www.findmykol.com/kol/sheila-lezcano","json_url":"https://www.findmykol.com/kol/sheila-lezcano/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"sheila-lezcano","name":"Sheila Lezcano","credential":"MD","specialty":"Rheumatology","specialty_raw":"Rheumatology","therapeutic_area":"Rheumatology/Immunology","therapeutic_areas":["Rheumatology/Immunology"],"institution":"Cedars-Sinai Medical Center","institution_url":"https://www.findmykol.com/institution/cedars-sinai-medical-center","city":"Los Angeles","state":"CA","region":{"label":"West","url":"https://www.findmykol.com/region/west"}},"identifiers":{"on_file":["npi","openalex"],"values":"Shown on the profile page to a signed-in account."},"summary":"Sheila Lezcano is a Rheumatology/Immunology physician affiliated with Cedars-Sinai Medical Center. OpenAlex indexes 15 publications with 723 citations (h-index 8).","overview":null,"focus":{"indications":[],"research_topics":["Rheumatology/Immunology"]},"scholarship":{"works_count":15,"cited_by_count":723,"h_index":8,"latest_activity_year":2025,"source":"works"},"payments":{"company_count":10,"program_years":{"first":2021,"last":null},"rows_total":17,"shown":3,"withheld":14,"rows":[{"payer":"ABBVIE INC.","program_year":2025,"amount_usd":144.32,"payment_count":13},{"payer":"GlaxoSmithKline, LLC.","program_year":2025,"amount_usd":31.76,"payment_count":1},{"payer":"ABBVIE INC.","program_year":2024,"amount_usd":180.85,"payment_count":12}],"source":"payments"},"prescribing":{"data_year":2023,"areas_total":8,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":37.6,"classes_total":8,"classes":[{"class":"Folate Analog Metabolic Inhibitor","setting":"prescribed","share_pct":11.1,"drugs":[{"name":"Methotrexate","share_pct":90.6},{"name":"Rasuvo","share_pct":9.4}],"max_beneficiaries":null},{"class":"TNF inhibitor","setting":"prescribed","share_pct":10.9,"drugs":[{"name":"Humira Pen","share_pct":33.7},{"name":"Enbrel Sureclick","share_pct":23.4},{"name":"Enbrel","share_pct":17.2},{"name":"Simponi","share_pct":12.8},{"name":"Enbrel Mini","share_pct":6.6},{"name":"Humira(Cf)","share_pct":6.2}],"max_beneficiaries":null}]},{"area":"Nervous system","share_pct":17.2,"classes_total":5,"classes":[{"class":"Gabapentinoids","setting":"prescribed","share_pct":8,"drugs":[{"name":"Gabapentin","share_pct":59.7},{"name":"Pregabalin","share_pct":40.3}],"max_beneficiaries":30},{"class":"Nonsteroidal Anti-inflammatory Drug","setting":"prescribed","share_pct":5.2,"drugs":[{"name":"Ibuprofen","share_pct":83.2},{"name":"Meloxicam","share_pct":16.8}],"max_beneficiaries":null}]},{"area":"Musculoskeletal","share_pct":13.4,"classes_total":5,"classes":[{"class":"Nonsteroidal Anti-inflammatory Drug","setting":"prescribed","share_pct":10,"drugs":[{"name":"Diclofenac Sodium","share_pct":80},{"name":"Naproxen","share_pct":13.2},{"name":"Sulindac","share_pct":6.8}],"max_beneficiaries":null},{"class":"RANK Ligand Inhibitor","setting":"prescribed","share_pct":1.1,"drugs":[{"name":"Prolia","share_pct":100}],"max_beneficiaries":18}]}],"care_setting":{"dominant":"facility","data_year":2023,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":15,"shown":5,"withheld":10,"matched_by":"OpenAlex author record","recent":[{"title":"Efficacy of the glucagon-like peptide-1 agonist exenatide in the treatment of short bowel syndrome","year":2011,"journal":"Neurogastroenterology & Motility","source_url":"https://doi.org/10.1111/j.1365-2982.2011.01723.x","status":"verified"},{"title":"Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth.","year":2009,"journal":"PubMed","status":"verified"},{"title":"New Clinical Method for Distinguishing D-IBS from Other Gastrointestinal Conditions Causing Diarrhea: The LA/IBS Diagnostic Strategy","year":2009,"journal":"Digestive Diseases and Sciences","source_url":"https://doi.org/10.1007/s10620-008-0694-z","status":"verified"},{"title":"M1808 Making IBS a “Diagnosis of Inclusion”: Development of a New Diagnostic Criteria for IBS","year":2008,"journal":"Gastroenterology","source_url":"https://doi.org/10.1016/s0016-5085(08)61979-4","status":"verified"},{"title":"A Systematic Review of Diagnostic Tests for Small Intestinal Bacterial Overgrowth","year":2007,"journal":"Digestive Diseases and Sciences","source_url":"https://doi.org/10.1007/s10620-007-0065-1","status":"verified"}],"source":"works"},"similar":[{"name":"Raj Makkar","slug":"raj-makkar","institution":"Cedars-Sinai Medical Center","specialty":"Interventional Cardiology","url":"https://www.findmykol.com/kol/raj-makkar","json_url":"https://www.findmykol.com/kol/raj-makkar/profile.json"},{"name":"Eduardo Marban","slug":"eduardo-marban","institution":"Cedars-Sinai Medical Center","specialty":"Cardiovascular Disease","url":"https://www.findmykol.com/kol/eduardo-marban","json_url":"https://www.findmykol.com/kol/eduardo-marban/profile.json"},{"name":"Robert Figlin","slug":"robert-figlin","institution":"Cedars-Sinai Medical Center","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/robert-figlin","json_url":"https://www.findmykol.com/kol/robert-figlin/profile.json"},{"name":"Shlomo Melmed","slug":"shlomo-melmed","institution":"Cedars-Sinai Medical Center","specialty":"Endocrinology, Diabetes & Metabolism","url":"https://www.findmykol.com/kol/shlomo-melmed","json_url":"https://www.findmykol.com/kol/shlomo-melmed/profile.json"},{"name":"David Felson","slug":"david-felson","institution":"Boston University","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/david-felson","json_url":"https://www.findmykol.com/kol/david-felson/profile.json"},{"name":"Marc Hochberg","slug":"marc-hochberg","institution":"University of Maryland School of Medicine","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/marc-hochberg","json_url":"https://www.findmykol.com/kol/marc-hochberg/profile.json"},{"name":"Philip Mease","slug":"philip-mease","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/philip-mease","json_url":"https://www.findmykol.com/kol/philip-mease/profile.json"},{"name":"Michelle Petri","slug":"michelle-petri","institution":"Johns Hopkins University School of Medicine","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/michelle-petri","json_url":"https://www.findmykol.com/kol/michelle-petri/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":14,"publications":10}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}